These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37990203)

  • 21. Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population.
    AbuDagga A; Sun SX; Tan H; Solem CT
    J Med Econ; 2013; 16(3):421-9. PubMed ID: 23336296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation.
    Lee Q; Mocarski M; Sun SX
    Am Health Drug Benefits; 2016 May; 9(3):140-50. PubMed ID: 27606039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare utilization, medical costs and mortality associated with malnutrition in patients with chronic obstructive pulmonary disease: a matched cohort study.
    Jerng JS; Tang CH; Cheng RW; Wang MY; Hung KY
    Curr Med Res Opin; 2019 Jul; 35(7):1265-1273. PubMed ID: 30676096
    [No Abstract]   [Full Text] [Related]  

  • 24. History of Asthma in Patients with Chronic Obstructive Pulmonary Disease. A Comparative Study of Economic Burden.
    Sadatsafavi M; Tavakoli H; Kendzerska T; Gershon A; To T; Aaron SD; FitzGerald JM;
    Ann Am Thorac Soc; 2016 Feb; 13(2):188-96. PubMed ID: 26599154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients.
    Ställberg B; Janson C; Larsson K; Johansson G; Kostikas K; Gruenberger JB; Gutzwiller FS; Jorgensen L; Uhde M; Lisspers K
    NPJ Prim Care Respir Med; 2018 Sep; 28(1):33. PubMed ID: 30202023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis.
    Buhl R; Wilke T; Picker N; Schmidt O; Hechtner M; Kondla A; Maywald U; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2355-2367. PubMed ID: 36172035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.
    Gerhardsson de Verdier M; Andersson M; Kern DM; Zhou S; Tunceli O
    Value Health; 2015 Sep; 18(6):759-66. PubMed ID: 26409602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of pulmonary hypertension on the outcomes of acute myocardial infarction patients with or without chronic obstructive pulmonary disease.
    Oh S; Kim JH; Cho KH; Kim MC; Sim DS; Hong YJ; Ahn Y; Jeong MH
    Medicine (Baltimore); 2022 Jan; 101(3):e28627. PubMed ID: 35060541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Ibáñez-Nolla J
    Lung; 2014 Aug; 192(4):505-18. PubMed ID: 24816902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data.
    Weiss TJ; Rosen Ramey D; Yang L; Liu X; Patel MJ; Rajpathak S; Bajwa EK; Lautsch D
    BMC Pulm Med; 2022 Oct; 22(1):383. PubMed ID: 36258171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
    Wan Y; Sun SX; Corman S; Huang X; Gao X; Shorr AF
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2127-36. PubMed ID: 26504378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
    Sethi S; Clark B; Bengtson LGS; Buysman EK; Palli S; Sargent A; Shaikh A; Ferguson GT
    Int J Chron Obstruct Pulmon Dis; 2023; 18():625-641. PubMed ID: 37155497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment.
    Davis JR; Kern DM; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
    J Manag Care Spec Pharm; 2016 Mar; 22(3):293-304. PubMed ID: 27003559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective observational study of asthma and chronic obstructive pulmonary disease prevalence and associated healthcare resource utilization in a large, integrated healthcare system.
    Collinsworth AW; Masica AL; Kudyakov R; Bayer V; Millard MW; Shaikh A
    Proc (Bayl Univ Med Cent); 2022; 35(6):737-745. PubMed ID: 36304620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs.
    Jain R; Cai Q; Sun SX; Tan H
    Manag Care; 2015 Aug; 24(8):40-8. PubMed ID: 26399141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.
    Barberà JA; Blanco I
    Drugs; 2009 Jun; 69(9):1153-71. PubMed ID: 19537834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study.
    Portillo EC; Pollack M; Lee I; Sun K; Zhao X; Kruse L; Feigler N; Patel S; Near AM
    Ther Adv Respir Dis; 2023; 17():17534666231164534. PubMed ID: 37013423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
    Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
    [No Abstract]   [Full Text] [Related]  

  • 39. Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with nebulized glycopyrrolate in the USA: a real-world data analysis.
    Niu X; Divino V; Sharma S; Dekoven M; Anupindi VR; Dembek C
    J Med Econ; 2021; 24(1):1-9. PubMed ID: 33143516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
    Bell CF; Blauer-Peterson C; Mao J
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.